Form 4: Ionis Pharmaceuticals Director Sells Shares Under 10b5-1 Trading Plan

Joseph Loscalzo, a director at Ionis Pharmaceuticals, sold 13,508 shares of common stock at a weighted average price of $37.861, as part of a pre-arranged 10b5-1 trading plan.

Summary

• Joseph Loscalzo, a director at Ionis Pharmaceuticals, executed a sale of 13,508 common stock shares.
• The sale occurred on November 12, 2024.
• The shares were sold at a weighted average price of $37.861.
• The sale was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on August 13, 2024.
• The price range for the transactions was between $37.62 and $38.595.
• Following the transaction, Loscalzo directly owns 32,251 shares of Ionis Pharmaceuticals common stock.

Sentiment

Score: 5

Explanation: The document is a routine disclosure of an insider stock sale under a pre-arranged plan, which is neither positive nor negative in itself. It is a neutral event.

Risks

• Sales by insiders, even under pre-arranged plans, can sometimes be perceived negatively by the market.

Industry Context

This is a routine disclosure of an insider stock sale, which is common in publicly traded companies. The use of a 10b5-1 plan indicates the sale was pre-planned and not based on any recent material non-public information.

Comparison to Industry Standards

• The use of a 10b5-1 trading plan is a standard practice for corporate insiders to avoid accusations of trading on non-public information, similar to practices at companies like Amgen, Biogen, and Gilead Sciences.
• The sale of shares by a director is a common occurrence and is not unusual in the biotech industry, where stock-based compensation is prevalent.

Stakeholder Impact

• The sale may have a minor impact on shareholders, but it is unlikely to be significant given the pre-planned nature of the transaction.

Key Dates

Keywords

Ionis Pharmaceuticals, insider trading, Form 4, stock sale, Rule 10b5-1, Joseph Loscalzo, director